Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1 per share in line with the Zacks Consensus Estimate. This compares to a loss of $1.02 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.95 per share when it actually produced a loss of $0.87, delivering a surprise of +8.42%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Viridian Therapeutics, which b ...